NEOGENOMICS INC (NEO) Form 8-K — Jul 28, 2026
NeoGenomics reported strong second quarter 2026 results, with total revenue increasing 11% year-over-year to $202 million. Clinical revenue grew 14% to $187 million, driven by a 26% increase in Next-Generation Sequencing (NGS) revenue, while adjusted EBITDA rose 36% to $14 million. The company raised its full-year 2026 guidance, now projecting consolidated revenue of $802 million to $806 million and adjusted EBITDA of $56 million to $58 million. GAAP net income for the quarter was $2 million, compared to a net loss of $45 million in the prior year period, which included an $11 million gain on the extinguishment of debt.
Key figures
- Eps
- 0.02
- Revenue
- 202000000
- Guidance
- Consolidated revenue $802 million to $806 million; Adjusted EBITDA $56 million to $58 million
- Net Income
- 2000000
- Revenue Yoy
- 11%
- Cash Position
- 146000000
- Shares Outstanding
- 129628000
- Adjusted EBITDA
- 14000000
- Revenue Per Test
- 515
- Clinical Revenue
- 187000000
- Share Repurchase Amount
- 25000000
- Debt Extinguishment Gain
- 11000000
- Convertible Notes Offering
- 316000000
- Convertible Notes Repurchased
- 276000000
Price after filing
Close on the filing date to close N calendar days later (from $14.24). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.